-
Mashup Score: 0
Addition of abiraterone acetate plus prednisone (AAP) to androgen deprivation therapy (ADT) with or without docetaxel (D) improved overall survival in patients with de novo metastatic castration sensitive prostate cancer in the PEACE-1 trial. The protocol was amended during the course of the study to assess whether addition of AAP increases bone loss.
Source: www.ejcancer.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 0
Results from this interim safety analysis of PEACE-3 confirm that patients with metastatic castration-resistant prostate cancer and bone metastases are at high risk of fractures, and the importance of prescribing a bone-protecting agent to prevent skeletal-related events in these patients.
Source: www.europeanurology.comCategories: General Medicine News, Oncologists1Tweet-
Decrease in Fracture Rate with Mandatory Bone-protecting Agents in the EORTC 1333/PEACE-3 Trial Comparing Radium-223 Combined with Enzalutamide Versus Enzalutamide Alone: A Safety Analysis - European Urology https://t.co/4YwoYVOmOk
-
-
Mashup Score: 0Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial - 27 day(s) ago
Sacituzumab govitecan (SG), a Trop-2-directed antibody–drug conjugate, demonstrated efficacy and manageable toxicity in the phase II TROPHY-U-01 study in pretreated advanced urothelial carcinoma (aUC). We report the results from final analysis of the global open-label randomized phase III TROPiCS-04 study (NCT04527991) in pretreated aUC.
Source: www.annalsofoncology.orgCategories: General Medicine News, Oncologists1Tweet-
Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial - Annals of Oncology https://t.co/BDzDLFPJRo
-
-
Mashup Score: 29
En Tactics organizamos actividades de formación médica continuada, congresos, e-learning, eventos corporativos, servicios de consultoría y gestión para sociedades científicas y grupos cooperativos.
Source: tacticsmd.netCategories: General Medicine News, Oncologists1Tweet-
¡Queda menos de 1 mes! Tenemos todo preparado para la II Jornada de Actualización en Uro-Oncología, el 25 de febrero en el Hospital Universitario La Paz (Madrid). ¡Te esperamos! Consulta el programa e inscríbete aquí: https://t.co/93mOAp7Egf https://t.co/t9kt9Qm2A2
-
-
Mashup Score: 1
MicroabstractCASSIOPE was a real-world study of cabozantinib use as a second-line or later-line therapy for advanced renal cell carcinoma after prior VEGF-targeted therapy. Of 679 patients prospectively enrolled in Europe, second-line or later-line cabozantinib use was shown to be effective and manageable in a real-world setting and had a safety profile consistent with previous studies.
Categories: General Medicine News, Oncologists1Tweet-
A Prospective Non-interventional Real-World Study of cabozantinib in Pretreated Patients With Advanced Renal Cell Carcinoma Refractory to Vascular Endothelial Growth Factor-Targeted Therapy (CASSIOPE) - Clinical Genitourinary Cancer https://t.co/D89nYMvyeE
-
-
Mashup Score: 1Prognostic and Predictive Role of SPOP Mutations in Prostate Cancer: A Systematic Review and Meta-analysis - 1 month(s) ago
Speckle-type POZ (SPOP) mutations could be a favorable prognostic factor in patients with prostate cancer (PC) and may also predict better overall and progression-free survival for treatment with hormonal agents. Therefore, less intensified treatments omitting chemotherapy for patients with SPOP-mutant PC should be explored in clinical trials.
Source: euoncology.europeanurology.comCategories: General Medicine News, Oncologists2Tweet-
Prognostic and Predictive Role of SPOP Mutations in Prostate Cancer: A Systematic Review and Meta-analysis - European Urology Oncology https://t.co/8eauKnqvjL
-
-
Mashup Score: 0Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC) - 1 month(s) ago
APCCC 2024 offers a unique platform for gathering the opinions of renowned prostate cancer experts who discuss and vote on unresolved questions that current literature and guidelines may not be able to address because of a lack of solid evidence.
Source: www.europeanurology.comCategories: General Medicine News, Oncologists1Tweet-
Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC) - European Urology https://t.co/LUpA2dRPFU
-
-
Mashup Score: 1
Radiopharmaceutical approaches to genitourinary cancers continue to expand. Nuclear medicine is broadening the search for new targets, renewing existing molecules to improve their specificity, biodistribution, and binding, and exploring “novel” isotopes. Interests focus on diagnostic tracers, theranostics, and combination treatments.
Source: www.europeanurology.comCategories: General Medicine News, Oncologists1Tweet-
Novel Radiopharmaceuticals and Future of Theranostics in Genitourinary Cancers - European Urology https://t.co/1Q6T79JuRD
-
-
Mashup Score: 27
En Tactics organizamos actividades de formación médica continuada, congresos, e-learning, eventos corporativos, servicios de consultoría y gestión para sociedades científicas y grupos cooperativos.
Source: tacticsmd.netCategories: General Medicine News, Oncologists1Tweet-
¡Queda menos de 1 mes! Tenemos todo preparado para la II Jornada de Actualización en Uro-Oncología, el 25 de febrero en el Hospital Universitario La Paz (Madrid). ¡Te esperamos! Consulta el programa e inscríbete aquí: https://t.co/93mOAp7Egf https://t.co/t9kt9Qm2A2
-
-
Mashup Score: 2Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma | NEJM - 1 month(s) ago
Muscle-invasive urothelial carcinoma is an aggressive disease with high rates of relapse. Whether pembrolizumab as adjuvant therapy would be effective in patients with high-risk muscle-invasive uro…
Source: www.nejm.orgCategories: General Medicine News, Oncologists1Tweet-
Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma | New England Journal of Medicine https://t.co/tRRDq3ykuq
-
Assessment of bone mineral density in men with de novo metastatic castration-sensitive prostate cancer treated with or without abiraterone acetate plus prednisone in the PEACE-1 phase 3 trial - European Journal of Cancer https://t.co/CiLua62Sx0